Implications for Neuromodulation Therapy to Control Inflammation and Related Organ Dysfunction in COVID-19

J Cardiovasc Transl Res. 2020 Dec;13(6):894-899. doi: 10.1007/s12265-020-10031-6. Epub 2020 May 26.

Abstract

COVID-19 is a syndrome that includes more than just isolated respiratory disease, as severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) also interacts with the cardiovascular, nervous, renal, and immune system at multiple levels, increasing morbidity in patients with underlying cardiometabolic conditions and inducing myocardial injury or dysfunction. Emerging evidence suggests that patients with the highest rate of morbidity and mortality following SARS-CoV2 infection have also developed a hyperinflammatory syndrome (also termed cytokine release syndrome). We lay out the potential contribution of a dysfunction in autonomic tone to the cytokine release syndrome and related multiorgan damage in COVID-19. We hypothesize that a cholinergic anti-inflammatory pathway could be targeted as a therapeutic avenue. Graphical Abstract .

Keywords: ACE2; COVID-19; SARS-CoV2; Vagus; Vagus nerve stimulation.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • COVID-19 / immunology
  • COVID-19 / therapy*
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Cholinergic Fibers* / immunology
  • Cholinergic Fibers* / virology
  • Cytokine Release Syndrome / immunology
  • Cytokine Release Syndrome / therapy*
  • Cytokine Release Syndrome / virology
  • Host-Pathogen Interactions
  • Humans
  • Inflammation / immunology
  • Inflammation / therapy*
  • Inflammation / virology
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / pathogenicity*
  • Treatment Outcome
  • Vagus Nerve Stimulation* / adverse effects